PA
RCUS icon

Profund Advisors’s Arcus Biosciences RCUS Stock Holding History

Profund Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
39,532
-14,631
-27% -$362K 0.03% 304
2026
Q1 		$1.17M Buy
54,163
+14,524
+37% +$314K 0.04% 310
2025
Q4 		$945K Buy
39,639
+22,048
+125% +$450K 0.03% 368
2025
Q3 		$239K Sell
17,591
-5,479
-24% -$57K 0.01% 877
2025
Q2 		$188K Sell
23,070
-2,088
-8% -$17.8K 0.01% 920
2025
Q1 		$197K Buy
25,158
+8,037
+47% +$93.2K 0.01% 909
2024
Q4 		$255K Sell
17,121
-1,599
-9% -$26.1K 0.01% 861
2024
Q3 		$286K Sell
18,720
-1,017
-5% -$16K 0.01% 829
2024
Q2 		$301K Sell
19,737
-34,693
-64% -$560K 0.01% 721
2024
Q1 		$1.03M Buy
54,430
+11,265
+26% +$195K 0.04% 354
2023
Q4 		$824K Sell
43,165
-7,906
-15% -$126K 0.04% 368
2023
Q3 		$917K Sell
51,071
-5,325
-9% -$107K 0.05% 306
2023
Q2 		$1.15M Sell
56,396
-21,376
-27% -$407K 0.06% 288
2023
Q1 		$1.42M Buy
+77,772
New +$1.49M 0.09% 196

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Profund Advisors's RCUS Position: Q2 2026 in Review

Profund Advisors reduced its Arcus Biosciences (RCUS) stake by 27% in Q2 2026, selling an estimated $362K and leaving 39,532 shares worth $1.22M. The position accounts for 0.03% of the portfolio, ranked #304.

Profund Advisors first reported a position in RCUS in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.42M in Q1 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Profund Advisors held 39,532 shares of Arcus Biosciences worth $1.22M as of Q2 2026.
  • Profund Advisors sold 14,631 Arcus Biosciences shares in Q2 2026, an estimated $362K.
  • Arcus Biosciences made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #304 holding.
  • Profund Advisors first reported a position in Arcus Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Arcus Biosciences position peaked at $1.42M in Q1 2023.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.